IN THE UNITED ST ES PATENT AND TRADEMARK OFFICE

Applicant : Anthony J.F. D'Apice et al.

Serial No.: 08/984,900

Filed : December 4, 19

Title

Art Unit : 1633

Examiner: S. Chen

: MATERIALS A **FOR MANAGEMENT OF HYPERACUTE**

REJECTION IN HOMEMOTRANSPLANTATION

Assistant Commissioner for Patents Washington, D.C. 20231

AMENDMENT AND RESPONSE

In response to the Office Action mailed October 1, 1999, Applicants submit the following amendments and remarks.

Kindly amend the application as follows:

In the Claims:

- [68] 69. (Amended) The porcine cell of claim 67, wherein the disruption is by the insertion of an exogenous sequence into said gone such that the disruption prevents expression of functional α -1,3 galactosyltransferase.
- [69] 70 (Amended) The porcine cell of claim 68, wherein said disruption is within exon 4, exon 7, exon 8, or exon 9 of the porcine \alpha -1,3 galactosyltransferase gene.
- [70] 71 (Amended) The porcine cell of claim 68, wherein said exogenous sequence is a selectable marker.
- [71] 72. (Amended) The porcine cell of claim 70, wherein said selectable marker is selected from the group consisting of the neo^R gene and the hyg^R gene.
- [72] 73. (Amended) The porcine cell of claim 68, wherein said exogenous sequence is flanked at its 5' and 3' ends by FRT DNA elements, and wherein stop codons have been inserted

CERHILICATE OF MAILING BY FIRST CLASS MAIL

Thereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patenti, Washington, D.C. 20231.